Welcome to our dedicated page for Defence Therapeu news (Ticker: DTCFF), a resource for investors and traders seeking the latest updates and insights on Defence Therapeu stock.
Defence Therapeutics Inc. (OTCQB: DTCFF) generates news primarily around its work as a biotechnology company specialized in drug delivery technologies and next-generation antibody-drug conjugates (ADCs). Company updates frequently highlight progress with its proprietary ACCUM® intracellular delivery platform, which Defence Therapeutics describes as enabling precision delivery of biologics and ADCs to target cells and enhancing efficacy and potency against cancer.
News coverage for Defence Therapeutics often focuses on scientific and preclinical milestones. The company has reported laboratory validations and preclinical in vivo studies of Accum®-enhanced ADCs, including comparative data in HER2-positive breast cancer models. Releases describe how ACCUM® can improve intracellular delivery, overcome endosomal entrapment, and increase the therapeutic index of ADCs, which the company associates with the potential for more effective and better-tolerated cancer therapies.
Another key theme in Defence Therapeutics news is its engagement with the global biopharma community. The company announces participation in events such as the World ADC Conference in San Diego and CPHI Worldwide in Frankfurt, where it presents new data, meets potential partners, and interacts with collaborators and shareholders. Updates also cover the formation of a Scientific Advisory Board to guide Accum®-enabled ADC programs and the appointment of leadership roles focused on quality and operations.
Investors and observers following DTCFF news will also see corporate and capital markets developments, including reports on convertible debenture conversions, stock option grants, warrant term amendments, marketing service engagements, and outcomes of annual general meetings. This news page brings together these scientific, strategic, and corporate updates so readers can track how Defence Therapeutics advances its ACCUM® platform and ADC-focused biotechnology strategy over time.
Defence Therapeutics (CSE: DTC) (OTCQB: DTCFF) is set to participate in the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting on June 11, 2024, in Toronto. This event is a key gathering for professionals involved in nuclear and molecular imaging. Defence will showcase AccuTRIC™, a novel Radio-Immuno-Conjugate developed with Orano Support SAS. AccuTRIC™ leverages Defence's AccuTOX® to enhance the treatment of hard-to-treat cancers. The technology aims to improve radiotherapy by using Auger electron emitter elements, which minimize damage to healthy tissues while maximizing therapeutic effects.
Defence Therapeutics announced the publication of a peer-reviewed study on AccuTOX, an anti-cancer molecule, in the Journal of Translational Medicine. The study details how AccuTOX synergizes with immune-checkpoint inhibitors to disrupt tumor growth. AccuTOX, derived from the Accum platform, shows enhanced killing potency, versatility, and ease of manufacturing. It induces immunogenic cell death and enhances cancer cell visibility to the immune system. The compound targets multiple cancer cell lines and has shown no apparent toxicity in animal models. Defence is initiating a Phase I trial and has submitted a CTA application to Health Canada.
Defence Therapeutics, a biopharmaceutical firm, announced the issuance and allowance of multiple patents across several Patent Families. The US Patent Office allowed application no. 18/169,440, enhancing the company's vaccine platform technology, Accum®, known for boosting antigen presentation. Recent pre-clinical studies using Defence's ARM-002™ vaccine showed significant antitumor responses, paving the way for Phase I trials.
Another patent in Australia for Defence's ADC platform was granted on February 1, 2024, further protecting Accum® and its variants, and adding to existing patents in the US, Japan, and Israel. Additionally, patents for Defence's vaccine platform technology were granted in Canada and Australia, with a Japanese patent expected soon. These patents cover methods and compositions for enhancing antigen immunogenicity.
CEO Mr. Plouffe highlighted the importance of these patents in Defence's mission to innovate and improve human health. The company is accelerating the examination of remaining applications via the Patent Prosecution Highway (PPH) program.
Defence Therapeutics Inc. announces successful completion of a pre-clinical vaccination trial using its ARM-002TM vaccine against pancreatic cancer, showing therapeutic effectiveness when combined with an immune-checkpoint inhibitor. Results reveal potent vaccine efficacy with tumor growth inhibition, positioning the company to target 'hard-to-treat' cancers like pancreatic cancer. The pancreatic cancer market is projected to exceed USD 36 billion by 2036.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.